Alyeska Investment Group
ADVM

Alyeska Investment Group’s Adverum Biotechnologies ADVM Stock Holding History

Alyeska Investment Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,508
Closed -$346K – 697
2021
Q1 		$346K Sell
3,508
-2,000
-36% -$240K ﹤0.01% 690
2020
Q4 		$597K Sell
5,508
-44
-0.8% -$5.44K 0.01% 441
2020
Q3 		$572K Buy
+5,552
New +$831K 0.01% 412
2018
Q2 		– Sell
-9,100
Closed -$528K – 450
2018
Q1 		$528K Buy
+9,100
New +$567K ﹤0.01% 414

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alyeska Investment Group's ADVM Position: Q2 2021 in Review

Alyeska Investment Group sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 3,508 shares — an estimated $346K sold.

Alyeska Investment Group first reported a position in ADVM in Q1 2018 and held it in 4 quarters. The position peaked at $597K in Q4 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Alyeska Investment Group reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 3,508 Adverum Biotechnologies shares in Q2 2021, an estimated $346K.
  • Alyeska Investment Group first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 4 quarters.
  • Alyeska Investment Group's Adverum Biotechnologies position peaked at $597K in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.